RET抑制剂Gavreto, FDA批准用于RET融合的转移性NSCLC

IF 1.4 4区医学 Q3 HEALTH CARE SCIENCES & SERVICES

American Health and Drug Benefits Pub Date : 2020-10-01

引用次数: 0

摘要

本节简要概述了2020年7月24日至2020年9月4日期间FDA批准的新型抗癌药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

本刊更多论文

Gavreto, RET Inhibitor, FDA Approved for Metastatic NSCLC with RET Fusions.

This section provides a brief overview of new cancer drugs approved by the FDA between July 24, 2020, and September 4, 2020.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

American Health and Drug Benefits Medicine-Health Policy

CiteScore

2.90

自引率

0.00%

发文量

期刊介绍： AHDB welcomes articles on clinical-, policy-, and business-related topics relevant to the integration of the forces in healthcare that affect the cost and quality of healthcare delivery, improve healthcare quality, and ultimately result in access to care, focusing on health organization structures and processes, health information, health policies, health and behavioral economics, as well as health technologies, products, and patient behaviors relevant to value-based quality of care.